These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30530134)

  • 21. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice.
    Villanueva V; López-González FJ; Mauri JA; Rodriguez-Uranga J; Olivé-Gadea M; Montoya J; Ruiz-Giménez J; Zurita J;
    Acta Neurol Scand; 2019 Apr; 139(4):360-368. PubMed ID: 30506559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals.
    Strzelczyk A; Steinig I; Willems LM; Reif PS; Senft C; Voss M; Gaida B; von Podewils F; Rosenow F
    Epilepsy Behav; 2017 May; 70(Pt A):177-181. PubMed ID: 28427029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis.
    Lattanzi S; De Maria G; Rosati E; Didato G; Chiesa V; Ranzato F; Canafoglia L; Cesnik E; Anzellotti F; Meletti S; Pauletto G; Nilo A; Bartolini E; Marino D; Tartara E; Luisi C; Bonanni P; Marrelli A; Stokelj D; Dainese F
    Epilepsia; 2021 Jan; 62(1):e1-e6. PubMed ID: 33314118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 30. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe.
    Steinhoff BJ; Christensen J; Doherty CP; Majoie M; De Backer M; Hellot S; Leunikava I; Leach JP
    Epilepsy Res; 2020 Sep; 165():106329. PubMed ID: 32623096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
    Steinhoff BJ; Klein P; Klitgaard H; Laloyaux C; Moseley BD; Ricchetti-Masterson K; Rosenow F; Sirven JI; Smith B; Stern JM; Toledo M; Zipfel PA; Villanueva V
    Epilepsy Behav; 2021 May; 118():107939. PubMed ID: 33839453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential role of brivaracetam in pediatric epilepsy.
    Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P
    Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
    Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K
    Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.